Nanoparticle-Based Vaccines Against Respiratory Viruses

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Feb 9

PMID 30733717

Citations 116

Authors

Soultan Al-Halifa

Laurie Gauthier

Dominic Arpin

Steve Bourgault

Denis Archambault

Affiliations

Soon will be listed here.

Abstract

The respiratory mucosa is the primary portal of entry for numerous viruses such as the respiratory syncytial virus, the influenza virus and the parainfluenza virus. These pathogens initially infect the upper respiratory tract and then reach the lower respiratory tract, leading to diseases. Vaccination is an affordable way to control the pathogenicity of viruses and constitutes the strategy of choice to fight against infections, including those leading to pulmonary diseases. Conventional vaccines based on live-attenuated pathogens present a risk of reversion to pathogenic virulence while inactivated pathogen vaccines often lead to a weak immune response. Subunit vaccines were developed to overcome these issues. However, these vaccines may suffer from a limited immunogenicity and, in most cases, the protection induced is only partial. A new generation of vaccines based on nanoparticles has shown great potential to address most of the limitations of conventional and subunit vaccines. This is due to recent advances in chemical and biological engineering, which allow the design of nanoparticles with a precise control over the size, shape, functionality and surface properties, leading to enhanced antigen presentation and strong immunogenicity. This short review provides an overview of the advantages associated with the use of nanoparticles as vaccine delivery platforms to immunize against respiratory viruses and highlights relevant examples demonstrating their potential as safe, effective and affordable vaccines.

Citing Articles

Revolutionizing Nanovaccines: A New Era of Immunization.

Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y Vaccines (Basel). 2025; 13(2).

PMID: 40006673 PMC: 11860605. DOI: 10.3390/vaccines13020126.

Viral Infection and Dissemination Through the Lymphatic System.

Brisse M, Hickman H Microorganisms. 2025; 13(2).

PMID: 40005808 PMC: 11858409. DOI: 10.3390/microorganisms13020443.

Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.

Petcherski A, Tingley B, Martin A, Adams S, Brownstein A, Steinberg R Life Sci Alliance. 2025; 8(4).

PMID: 39900438 PMC: 11790838. DOI: 10.26508/lsa.202403182.

A modular protocol for virosome display of subunit vaccine antigens.

Rosado V, Adams L, Yousif A, Sangesland M, Ronsard L, Okonkwo V STAR Protoc. 2025; 6(1):103610.

PMID: 39891914 PMC: 11834092. DOI: 10.1016/j.xpro.2025.103610.

Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.

Zhou M, Xiao H, Yang X, Cheng T, Yuan L, Xia N MedComm (2020). 2025; 6(2):e70056.

PMID: 39830020 PMC: 11739453. DOI: 10.1002/mco2.70056.

References

Lynn G, Laga R, Darrah P, Ishizuka A, Balaci A, Dulcey A . In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol. 2015; 33(11):1201-10. PMC: 5842712. DOI: 10.1038/nbt.3371. View

Hall K, Blair Zajdel M, Blair G . Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. Biochem J. 2010; 431(3):321-36. DOI: 10.1042/BJ20100766. View

Kumari A, Singla R, Guliani A, Yadav S . Nanoencapsulation for drug delivery. EXCLI J. 2015; 13:265-86. PMC: 4464443. View

Abderrazak A, Syrovets T, Couchie D, El Hadri K, Friguet B, Simmet T . NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 2015; 4:296-307. PMC: 4315937. DOI: 10.1016/j.redox.2015.01.008. View

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

Niu Y, Yu M, Hartono S, Yang J, Xu H, Zhang H . Nanoparticles mimicking viral surface topography for enhanced cellular delivery. Adv Mater. 2013; 25(43):6233-7. DOI: 10.1002/adma.201302737. View

Kushnir N, Streatfield S, Yusibov V . Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012; 31(1):58-83. PMC: 7115575. DOI: 10.1016/j.vaccine.2012.10.083. View

Silva A, Soema P, Slutter B, Ossendorp F, Jiskoot W . PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccin Immunother. 2016; 12(4):1056-69. PMC: 4962933. DOI: 10.1080/21645515.2015.1117714. View

Laval J, Mazeran P, Thomas D . Nanobiotechnology and its role in the development of new analytical devices. Analyst. 2000; 125(1):29-33. DOI: 10.1039/a907827d. View

10.

Ulery B, Petersen L, Phanse Y, Kong C, Broderick S, Kumar D . Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci Rep. 2012; 1:198. PMC: 3240970. DOI: 10.1038/srep00198. View

11.

Masters S, Dunne A, Subramanian S, Hull R, Tannahill G, Sharp F . Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010; 11(10):897-904. PMC: 3103663. DOI: 10.1038/ni.1935. View

12.

Branche A, Falsey A . Parainfluenza Virus Infection. Semin Respir Crit Care Med. 2016; 37(4):538-54. PMC: 7171724. DOI: 10.1055/s-0036-1584798. View

13.

Mamo T, Poland G . Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering. Vaccine. 2012; 30(47):6609-11. DOI: 10.1016/j.vaccine.2012.08.023. View

14.

Therien A, Bedard M, Carignan D, Rioux G, Gauthier-Landry L, Laliberte-Gagne M . A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling. J Nanobiotechnology. 2017; 15(1):54. PMC: 5516373. DOI: 10.1186/s12951-017-0289-y. View

15.

Carter N, Curran M . Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011; 71(12):1591-622. DOI: 10.2165/11206860-000000000-00000. View

16.

Francica J, Lynn G, Laga R, Joyce M, Ruckwardt T, Morabito K . Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjug Chem. 2016; 27(10):2372-2385. DOI: 10.1021/acs.bioconjchem.6b00370. View

17.

Lee Y, Ko E, Lee Y, Kim K, Kim M, Lee Y . Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. PLoS One. 2018; 13(1):e0190868. PMC: 5764335. DOI: 10.1371/journal.pone.0190868. View

18.

Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T . Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine. 2009; 27(42):5896-905. DOI: 10.1016/j.vaccine.2009.07.037. View

19.

Ross K, Haughney S, Petersen L, Boggiatto P, Wannemuehler M, Narasimhan B . Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours. Adv Healthc Mater. 2014; 3(7):1071-7. DOI: 10.1002/adhm.201300525. View

20.

Lamb R, Choppin P . The gene structure and replication of influenza virus. Annu Rev Biochem. 1983; 52:467-506. DOI: 10.1146/annurev.bi.52.070183.002343. View